Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation

J. Zuber, M. Le Quintrec, S. Krid, C. Bertoye, V. Gueutin, A. Lahoche, N. Heyne, G. Ardissino, V. Chatelet, L. H. Noël, M. Hourmant, P. Niaudet, V. Frémeaux-Bacchi, E. Rondeau, C. Legendre, C. Loirat

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Eculizumab (anti-C5) has been sporadically reported as an efficient therapy for atypical hemolytic uremic syndrome (aHUS). However, the lack of series precludes any firm conclusion about the optimal use of anti-C5 for preventing or treating aHUS posttransplant aHUS recurrence. We thoroughly studied 22 renal transplant recipients with aHUS who received off-label therapy with anti-C5, including 12 cases, which have not been reported yet. Nine patients, all carrying a complement genetic abnormality associated with a high risk of aHUS recurrence, received prophylactic anti-C5 therapy to prevent posttransplant recurrence. Eight of them had a successful recurrence-free posttransplant course and achieved a satisfactory graft function, while the remaining patient experienced early arterial thrombosis of the graft. Thirteen renal transplant recipients were given anti-C5 for posttransplant aHUS recurrence. A complete reversal of aHUS activity was obtained in all of them. Importantly, the delay of anti-C5 initiation after the onset of the aHUS episode inversely correlated with the degree of renal function improvement. Three patients in whom anti-C5 was subsequently stopped experienced a relapse. Altogether these data suggest that long-term eculizumab is highly effective for preventing and treating posttransplant aHUS recurrence. Our study also indicates that anti-C5 should be promptly started if a recurrence occurs.

Original languageEnglish
Pages (from-to)3337-3354
Number of pages18
JournalAmerican Journal of Transplantation
Volume12
Issue number12
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Kidney Transplantation
Recurrence
Kidney
Transplants
eculizumab
Atypical Hemolytic Uremic Syndrome
Thrombosis
Therapeutics

Keywords

  • Atypical hemolytic uremic syndrome
  • eculizumab
  • renal transplant recipient

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Zuber, J., Le Quintrec, M., Krid, S., Bertoye, C., Gueutin, V., Lahoche, A., ... Loirat, C. (2012). Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. American Journal of Transplantation, 12(12), 3337-3354. https://doi.org/10.1111/j.1600-6143.2012.04252.x

Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. / Zuber, J.; Le Quintrec, M.; Krid, S.; Bertoye, C.; Gueutin, V.; Lahoche, A.; Heyne, N.; Ardissino, G.; Chatelet, V.; Noël, L. H.; Hourmant, M.; Niaudet, P.; Frémeaux-Bacchi, V.; Rondeau, E.; Legendre, C.; Loirat, C.

In: American Journal of Transplantation, Vol. 12, No. 12, 12.2012, p. 3337-3354.

Research output: Contribution to journalArticle

Zuber, J, Le Quintrec, M, Krid, S, Bertoye, C, Gueutin, V, Lahoche, A, Heyne, N, Ardissino, G, Chatelet, V, Noël, LH, Hourmant, M, Niaudet, P, Frémeaux-Bacchi, V, Rondeau, E, Legendre, C & Loirat, C 2012, 'Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation', American Journal of Transplantation, vol. 12, no. 12, pp. 3337-3354. https://doi.org/10.1111/j.1600-6143.2012.04252.x
Zuber, J. ; Le Quintrec, M. ; Krid, S. ; Bertoye, C. ; Gueutin, V. ; Lahoche, A. ; Heyne, N. ; Ardissino, G. ; Chatelet, V. ; Noël, L. H. ; Hourmant, M. ; Niaudet, P. ; Frémeaux-Bacchi, V. ; Rondeau, E. ; Legendre, C. ; Loirat, C. / Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. In: American Journal of Transplantation. 2012 ; Vol. 12, No. 12. pp. 3337-3354.
@article{10b93669d2db4dd3850c9709a76541a9,
title = "Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation",
abstract = "Eculizumab (anti-C5) has been sporadically reported as an efficient therapy for atypical hemolytic uremic syndrome (aHUS). However, the lack of series precludes any firm conclusion about the optimal use of anti-C5 for preventing or treating aHUS posttransplant aHUS recurrence. We thoroughly studied 22 renal transplant recipients with aHUS who received off-label therapy with anti-C5, including 12 cases, which have not been reported yet. Nine patients, all carrying a complement genetic abnormality associated with a high risk of aHUS recurrence, received prophylactic anti-C5 therapy to prevent posttransplant recurrence. Eight of them had a successful recurrence-free posttransplant course and achieved a satisfactory graft function, while the remaining patient experienced early arterial thrombosis of the graft. Thirteen renal transplant recipients were given anti-C5 for posttransplant aHUS recurrence. A complete reversal of aHUS activity was obtained in all of them. Importantly, the delay of anti-C5 initiation after the onset of the aHUS episode inversely correlated with the degree of renal function improvement. Three patients in whom anti-C5 was subsequently stopped experienced a relapse. Altogether these data suggest that long-term eculizumab is highly effective for preventing and treating posttransplant aHUS recurrence. Our study also indicates that anti-C5 should be promptly started if a recurrence occurs.",
keywords = "Atypical hemolytic uremic syndrome, eculizumab, renal transplant recipient",
author = "J. Zuber and {Le Quintrec}, M. and S. Krid and C. Bertoye and V. Gueutin and A. Lahoche and N. Heyne and G. Ardissino and V. Chatelet and No{\"e}l, {L. H.} and M. Hourmant and P. Niaudet and V. Fr{\'e}meaux-Bacchi and E. Rondeau and C. Legendre and C. Loirat",
year = "2012",
month = "12",
doi = "10.1111/j.1600-6143.2012.04252.x",
language = "English",
volume = "12",
pages = "3337--3354",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation

AU - Zuber, J.

AU - Le Quintrec, M.

AU - Krid, S.

AU - Bertoye, C.

AU - Gueutin, V.

AU - Lahoche, A.

AU - Heyne, N.

AU - Ardissino, G.

AU - Chatelet, V.

AU - Noël, L. H.

AU - Hourmant, M.

AU - Niaudet, P.

AU - Frémeaux-Bacchi, V.

AU - Rondeau, E.

AU - Legendre, C.

AU - Loirat, C.

PY - 2012/12

Y1 - 2012/12

N2 - Eculizumab (anti-C5) has been sporadically reported as an efficient therapy for atypical hemolytic uremic syndrome (aHUS). However, the lack of series precludes any firm conclusion about the optimal use of anti-C5 for preventing or treating aHUS posttransplant aHUS recurrence. We thoroughly studied 22 renal transplant recipients with aHUS who received off-label therapy with anti-C5, including 12 cases, which have not been reported yet. Nine patients, all carrying a complement genetic abnormality associated with a high risk of aHUS recurrence, received prophylactic anti-C5 therapy to prevent posttransplant recurrence. Eight of them had a successful recurrence-free posttransplant course and achieved a satisfactory graft function, while the remaining patient experienced early arterial thrombosis of the graft. Thirteen renal transplant recipients were given anti-C5 for posttransplant aHUS recurrence. A complete reversal of aHUS activity was obtained in all of them. Importantly, the delay of anti-C5 initiation after the onset of the aHUS episode inversely correlated with the degree of renal function improvement. Three patients in whom anti-C5 was subsequently stopped experienced a relapse. Altogether these data suggest that long-term eculizumab is highly effective for preventing and treating posttransplant aHUS recurrence. Our study also indicates that anti-C5 should be promptly started if a recurrence occurs.

AB - Eculizumab (anti-C5) has been sporadically reported as an efficient therapy for atypical hemolytic uremic syndrome (aHUS). However, the lack of series precludes any firm conclusion about the optimal use of anti-C5 for preventing or treating aHUS posttransplant aHUS recurrence. We thoroughly studied 22 renal transplant recipients with aHUS who received off-label therapy with anti-C5, including 12 cases, which have not been reported yet. Nine patients, all carrying a complement genetic abnormality associated with a high risk of aHUS recurrence, received prophylactic anti-C5 therapy to prevent posttransplant recurrence. Eight of them had a successful recurrence-free posttransplant course and achieved a satisfactory graft function, while the remaining patient experienced early arterial thrombosis of the graft. Thirteen renal transplant recipients were given anti-C5 for posttransplant aHUS recurrence. A complete reversal of aHUS activity was obtained in all of them. Importantly, the delay of anti-C5 initiation after the onset of the aHUS episode inversely correlated with the degree of renal function improvement. Three patients in whom anti-C5 was subsequently stopped experienced a relapse. Altogether these data suggest that long-term eculizumab is highly effective for preventing and treating posttransplant aHUS recurrence. Our study also indicates that anti-C5 should be promptly started if a recurrence occurs.

KW - Atypical hemolytic uremic syndrome

KW - eculizumab

KW - renal transplant recipient

UR - http://www.scopus.com/inward/record.url?scp=84870534251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870534251&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2012.04252.x

DO - 10.1111/j.1600-6143.2012.04252.x

M3 - Article

VL - 12

SP - 3337

EP - 3354

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 12

ER -